Business
Dermapharm Holding SE: Annual General Meeting Resolves Dividend Distribution of EUR 0.90 Per Share
2025 outlook confirmed Board of Management and Supervisory Board actions ratified with large majority Shareholders resolve dividend payment of EUR 0.90 per share GRUNWALD, Germany - June 26, 2025 (NEWMEDIAWIRE) - Dermapharm Holding SE ("Dermap...
About this update from Dermapharm Holding Se
[{"type":"table","headerItems":[],"items":[{"val":[{"val":[{"type":"list","items":[{"val":[{"type":"text","content":"2025 outlook confirmed","length":22,"tagName":"p"}]},{"val":[{"type":"text","content":"Board of Management and Supervisory Board actions ratified with large majority","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"Shareholders resolve dividend payment of EUR 0.90 per share","length":59,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":159,"olType":false},{"type":"text","content":"GRUNWALD, Germany - June 26, 2025 (NEWMEDIAWIRE) - Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today held its Annual General Meeting for financial year 2024. 14.6% of the share capital was in attendance at the Annual General Meeting, which was held in person. The majority of shareholders voted in line with the management's proposals under every agenda item.","length":456,"tagName":"p"},{"type":"text","content":"The Annual General Meeting ratified the actions of all members of the Board of Management and of the Supervisory Board for financial year 2024 with a(n) 99.2% and 89.4% majority of votes cast, respectively. The Annual General Meeting acted on the recommendation of the Board of Management and the Supervisory Board to distribute a dividend of EUR 0.90 per share carrying dividend rights. The total distribution amounts to EUR 48.5 million, representing a distribution ratio of approximately 43% of the consolidated net profit eligible for distribution.","length":552,"tagName":"p"},{"type":"text","content":"Grant Thornton AG Wirtschaftsprufungsgesellschaft was re-elected as the auditor for the current financial year. RSM Ebner Stolz GmbH & Co. KG Wirtschaftsprufungsgesellschaft Steuerberatungsgesellschaft was chosen as auditor for the sustainability reporting. This is subject to the Corporate Sustainability Reporting Directive (CSRD) being transposed into national law, which will trigger the obligation to have the sustainability reporting for financial year 2025 audited. The detailed results of the voting for each agenda item are available on the Company website https://ir.dermapharm.de/en/investor-relations/annual-general-meeting/ in the "Voting results" section under "Annual General Meeting 2025".","length":729,"tagN...